- CE: 1.50
- CME: 1.25
- Course opens: Thu, May 01 2014
- Course expires: Sat, Apr 30 2016
- Non-member Cost: $0.00
Now that the FDA has approved the first sublingual immunotherapy (SLIT) products for use in the United States, allergist/immunologists have new options to consider when treating their patients who could benefit from allergen immunotherapy. This presentation - a recording of a symposium presented at the 2014 AAAAI Annual Meeting - provides an overview of the mechanisms of SLIT, a summary of the results of clinical trials with these new forms of immunotherapy, and a discussion of how to incorporate the administration of SLIT into an allergy/immunology practice.
- Review how SLIT works.
- Discuss the results of pivotal SLIT clinical trials.
- Describe how to use SLIT in practice.
Allied Health Professionals working in allergy/immunology practices